GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2009

Recently Spun Out Axikin Obtains $3M Series A Financing

  • Axikin Pharmaceuticals will receive $3 million through a series A private placement of its stock. The company was formed as a spinout from Actimis Pharmaceuticals following the acquisition of Actimis' lead program by Boehringer Ingelheim in a structured buyout in June 2008.

    Axikin's pipeline includes an advanced preclinical program with multiple small molecule lead candidates and two additional novel target research programs. These programs are expected to have broad applications across respiratory and allergic diseases including asthma, allergic rhinitis, and COPD.

    The financing was led by Sanderling Ventures, and additional investors included Mitsui & Co. Venture Partners.

    ---

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?